The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- Researchers combine immunotherapy with nano-particles to kill cancer cells – The Brussels Times
- New Approaches in Breast Cancer Therapy Through Green Nanotechnology a | IJN – Dove Medical Press
- Complete Overview of Cancer Nanomedicine Market to Witness High Rate of Growth in Forthcoming Years – Fusion Science Academy
- Controlled phage therapy hints at future alternative to antibiotics – New Atlas
- Healthcare IT Market trends research and projections – GroundAlerts.com
|Search Immortality Topics:|
Category Archives: Pharmacogenomics
In the future, nutritionists and dietitians will have a new tool for studying the relationship between a persons nutrition and health theyll be adding DNA into the mix.
Manchester University is moving ahead with plans to offer a master of science degree in nutrition and nutrigenomics (MSNGx).
It builds on Manchesters masters degree in pharmacogenomics, which is the study of DNA and medication. Manchester is the first university in the nation to offer that degree.
To our knowledge, the MSNGx program would be the first of its kind in the country, said Teresa Beam, Pharmaceutical Sciences Department chair and professor of pharmaceutical sciences and pharmacogenomics at Manchesters Fort Wayne campus.
Manchester University will train the nutritionist of the future, she said. The program will be divided into two phases: three years of undergraduate study at the North Manchester campus and two years of professional study at the Fort Wayne campus.
Jeff Beer will be responsible for the first three years the undergraduate phase. Beam will lead the graduate-level phase in Fort Wayne.
In lay terms, the program will teach nutritionists how to use an individuals DNA to make better nutrition choices. Beam said eventually, with additional research the body of evidence will grow and nutritionists and dietitians will be better able to match diets to genes, the gut microbiome and metabolism.
The ultimate goal of this new field, Beam said, is to use nutrigenomics to improve health and make healthier communities. Complex diseases such as cancer, diabetes and heart disease could some day be better managed when an NGx-trained nutritionist is part of patients health care teams.
The importance of diet in preventing and treating complex diseases is well-known, she said. Food as medicine is emerging as a necessary component of managing complex diseases.
In Spring 2020 the university plans to hire an MSNGx program director. By the end of 2020 the MSNGx application should be submitted to the accrediting council. The accreditation site visit will be in spring of 2022 and the first students will be admitted in fall 2022.
Nutrigenomics also has the potential to improve athletic performance. Genetics can influence the bodys ability to recover from injury, generate inflammation or cause oxidative stress, Beam said. Genetics can also affect performance. All are factors that can be considered when constructing athletic training regimens, designing physical therapy treatments or optimizing game strategies.
Read more from the original source:
Manchester to add master's degree in nutrition with DNA twist - FW Business
Global Pharmacogenomics (PGx) by leading manufacturers with its application and types 2020 2025| Abbott Laboratories, Affymetrix, Inc. – News Log…
Los Angeles, United State,January 2020 :
The report attempts to offer high-quality and accurate analysis of the global Pharmacogenomics (PGx) market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Pharmacogenomics (PGx) market that are impacting their business. Readers can become aware of crucial opportunities available in the global Pharmacogenomics (PGx) market as well as key factors driving and arresting market growth. The research study also provides deep geographical analysis of the global Pharmacogenomics (PGx) market and sheds light on important applications and products that market players can focus on for achieving strong growth.
Major players profiled in the report
We follow industry-best practices and primary and secondary research methodologies to prepare our market research publications. Our analysts take references from company websites, government documents, press releases, and financial reports and conduct face-to-face or telephonic interviews with industry experts for collecting information and data. There is one complete section of the report dedicated for authors list, data sources, methodology/research approach, and publishers disclaimer. Then there is another section that includes research findings and conclusion.
Get PDF template of Pharmacogenomics (PGx) market report@ https://www.qyresearch.com/sample-form/form/994732/global-Pharmacogenomics-PGx-market
This report focuses on the global top players, coveredAbbott LaboratoriesAffymetrix, Inc.Assurex Health, IncAstrazenecaGeneDXIllumina, Inc.Laboratory Corporation of America HoldingsMyriad Genetics, Inc.Pathway GenomicsPfizer, IncQiagen, Inc.RochegTeva Pharmaceutical Industries Ltd.Thermo Fisher ScientificTransgenomic, Inc.
Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa
Market segment by Type, the product can be split intoPolymerase Chain Reaction (PCR)MicroarraySequencingOther
Market segment by Application, the market can be split intoCardiovascular Diseases (CVD)Central Nervous System (CNS)Cancer/OncologyInfectious DiseasesOther
Besides short-term and long-term estimations related to the global Pharmacogenomics (PGx) market, we provide you with demand, consumption, growth, and various other forecasts. We take your specific requirements into consideration and provide you the most applicable forecasts for the market. You can simplify your critical decision-making process using our forecasts on the global market. Our unbiased insights into critical aspects of the market will assist you to strengthen your market position and ensure lasting success in the long run. They will also help you to address the challenges you face in the market when reaching your milestones.
Our analysts are not only experts in preparing accurate and detailed market research reports but also customizing them according to your business needs. We can customize this entire report on the global Pharmacogenomics (PGx) market and also specific sections such as financial analysis, competitive intelligence, insights and innovation, target market analysis, strategy and planning, and market analysis. Our report customization can cover merger and acquisition screening, IPO prospectus, economic impact analysis, industry benchmarking, competitive landscape, due diligence, and company analysis.
Apart from the sections mentioned above, our report on the global Pharmacogenomics (PGx) market can be customized keeping in view other aspects such as research and development landscape, patent analysis, product competition, mega trend analysis, marketing mix modeling, go-to-market strategy, technology, B2B survey, and strategic frameworks. Furthermore, you can ask for customization of market scenario analysis, strategic recommendations, market potential analysis, identification of opportunities, market forecasting, market entry, market sizing, market attractiveness, and market segmentation.
Table of Contents
Study Coverage: This is the first section of the report that includes highlights of market segmentation, years covered, study objectives, major manufactures of the global Pharmacogenomics (PGx) market, and product scope.
Executive Summary: Here, the report sheds light on production, revenue, consumption, and capacity of the market. It also brings to light macroscopic indicators, drivers, restraints, and trends of the market.
Manufacturer Profiles: This section gives broad analysis of key players of the global Pharmacogenomics (PGx) market on the basis of different factors such as recent developments, market share, and gross margin. It also provides SWOT analysis.
Production by Region: All of the regions analyzed in the report are studied here based on key factors such as production, revenue, market share, and import and export.
Consumption by Region: Each regional market studied here is analyzed on the basis of consumption and consumption share of the global market.
Market Size by Product: It includes price, revenue, and market breakdown analysis by type of product.
Market Size by Application: It includes consumption, breakdown data, and consumption share analysis by application.
The report answers several questions about the Pharmacogenomics (PGx) market includes:
What will be the market size of Pharmacogenomics (PGx) market in 2025?What will be the Pharmacogenomics (PGx) growth rate in 2025?Which key factors drive the market?Who are the key market players for Pharmacogenomics (PGx)?Which strategies are used by top players in the market?What are the key market trends in Pharmacogenomics (PGx)?Which trends and challenges will influence the growth of market?Which barriers do the Pharmacogenomics (PGx) markets face?What are the market opportunities for vendors and what are the threats faced by them?What are the most important outcomes of the five forces analysis of the Pharmacogenomics (PGx) market?
Get Customized Report in your Inbox within 24 hours@ https://www.qyresearch.com/customize-request/form/994732/global-Pharmacogenomics-PGx-market
Contact US:QY Research, INC.17890 Castleton, Suite 218,Los Angeles, CA 91748USA: +1 626 295 2442China: +86 1082 945 717Japan: +81 9048 009 273India: +91 9766 478 224Emails email@example.com
We don't always get what we want. But that shouldn't stop us from wishing, right?
So we reached out to executives around healthcare to get their wish lists for the industry as we enter the next decade.
From taking on regulatory requirements to better harnessing telehealth, here's what they had to say.
Top health industry issues of 2020: Will digital start to show an ROI?
Each year, PwC's Health Research Institute (HRI) names the top issues for the health industry in the coming year. What made the list for 2020? Join HRI for a discussion of the most important trends for providers, insurers, pharma/life sciences and employers.
"With the continued focus on bringing down the cost of healthcare, payers and employers will increasingly join providers in urging people to access the right level of care in lower-acuity settings rather than going to the ED. This will continue the acceleration of consumer-direct access to care options such as in-home, digital and local retail locations."
We need to move away from politics as usual. It is my hope that we can come together to drive solutions that make our healthcare system more efficient and prioritize the patients needs above all. Lets remove regulatory requirements to empower providers to focus on the delivery of care instead of needless administration. As the worlds largest economy, we simply have to prioritize the health of all of our people."
Lloyd Dean, co-CEO of CommonSpirit Health
"Top of mind is increased focus on using telehealth to meet the needs of the most vulnerable: the oldest and youngest on the spectrum as well as the sickest and poorest.
Weve gotten good at targeting telehealth to younger, tech-savvier, affluent patients in their 20s, 30s and 40s. But we need to pay closer attention to where telehealth is needed most and can have a profound impact. Telehealth holds strong potential to help patients with serious and chronic conditions, such as cancer, diabetes and COPD, who typically require more frequent engagement to stay out of the hospital.
Roy Schoenberg, M.D., president and CEO, American Well
"Id like to see the industry adopt more care management policies that encourage patients to manage their safety, healthcare and data via tested digital applications. In 2020 there should be greater adoption and more rapid application of pharmacogenomics into workflow process for patients and prescribers. The fact that the FDA is holding back pharmacogenomics is short-sighted. Pharmacogenomics ought to be fully embraced along with pharmacists who use technology-enabled tools to clinically apply data real-time and store data for future use as well.
Care practices should also be expanded so that pharmacists can be first-line primary care providers through physician collaboration or on their own. As healthcare organizations and payers transform how healthcare is defined and paid for, it will essential for pharmacists to step out from behind the counter to play a larger role in advising care, managing treatment and other clinical care services such as approving refills based on certain parameters."
Orsula V. Knowlton, president, chief marketing/new business development officer,Tabula Rasa HealthCare
"With impeachment looming and the 2020 presidential election set to take center stage, it will be hard for antimicrobial resistance to break through the noise in the media. I hope to read that Washington lawmakers put partisan politics aside and prioritize policies that will save millions of lives. When it comes to legislation to fight superbugs, we need a package of incentivesincluding Medicare reimbursement reforms, pull incentives to reward FDA approval of novel antimicrobials and push incentives to support research and development programs.
The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act is a good first step. The DISARM Act would increase Medicare funding to hospitals that appropriately use innovative antibiotics. The Centers for Medicare & Medicaid Services recently finalized a rule that would allow hospitals to receive additional Medicare reimbursement for prescribing newer antibiotics to treat drug-resistant infections. I hope to see more policy solutions that build on the DISARM Act to incentivize drug companies to fund antibiotic research."
GregFrank, director of Working to Fight AMR
Say goodbye to insulin injections and hello to snake toxins.
From penicillin to 3D-printed kidneys, the medical field has long served as a major catalyst of human ingenuity. In Colorado, that innovation doesnt appear to be slowing down. Centennial State institutions are helping pioneer treatments that could revolutionize health careboth today and in the years ahead.
A Gilded PillAbout 416,000 adults in Colorado suffer from diabetes. No wonder, then, that oral insulin (read: no more needles) is considered the holy grail of diabetes care. Denvers Creekside Endocrine Associates is part of the quest as one of only 37 places in the country testing an insulin pill developed by New Yorks Oramed Pharmaceutical. The key is ensuring the capsule reaches the liver before dissolving in stomach acid. If successful, the pill could also drastically lower the average cost of diabetes care, which is currently nearly $10,000 a year in the United States.
Conversation StarterThis past August, UCHealth introduced the world to Alexas nerdy cousin, Livi. An artificial-intelligence-based virtual assistant, Livi can be summoned on an Amazon Echo by saying Alexa, ask UCHealth. Users can then pepper her with commands like Email me information on Crohns disease or Find me a neurologist, and Livi will consult network sources to locate the information. UCHealth hopes to expand Livis capabilities over the next few years. This fall, for example, she was integrated into its electronic medical record system and mobile app so she can check your test results and appointment times.
Game TheoryIn 2017, Childrens Hospital Colorado unveiled one of the first full-time hospital gaming and technology departments in the world. Patients with movement-debilitating illnesses such as cerebral palsy get the much-needed, potentially dexterity-improving activity they require by donning virtual reality and augmented reality headsets and, for example, exploring alien planets. The diversions can also make it easier for kids to undergo difficult treatments: The anxiety a child feels before a lumbar puncturean injection of medicine into her spinal fluidmight be lessened if she can confront the procedure while wielding a lightsaber.
Snake Venom SalesmanA professor at the University of Northern Colorado might have finally found a way for serpents to pay penance for the whole exile-from-Eden thing: Stephen Mackessys Venom Analysis Lab, which launched in the mid-1990s, has shown that toxins from some venomous snakes are capable of preventing cancer cells from metastasizing. The next step (likely still years away) is finding an application method that would weaponize compounds in the venom against a humans cancer without harming the humans body.
Good GenesBoth Lutheran Medical Center and Kaiser Permanente are early practitioners of pharmacogenomicsbasically, how your DNA affects your bodys reactions to medicines. In Lutherans pilot program, primary care providers give some patients the option of a 20-second cheek swab. Pharmacists and doctors can use subsequent genetic-testing reports to provide recommendations, such as lowering a dosage because genetic traits reveal your body might absorb drugs faster or suggesting you avoid a particular medication.
This article appeared in the 2020 issue of 5280 Health.
The global modular laboratory automation market at a CAGR of over 6% during the forecast period – P&T Community
NEW YORK, Dec. 26, 2019 /PRNewswire/ --
Global Modular Laboratory Automation Market: About this market This modular laboratory automation market analysis considers sales from hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, and other end-users. Our study also finds the sales of modular laboratory automation in Asia, Europe, North America, and ROW. In 2019, the hospitals and diagnostic laboratories segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing prevalence of chronic and infectious diseases such as cancer, diabetes, influenza, and cardiovascular will play a significant role in the hospitals and diagnostic laboratories segment to maintain its market position. Also, our global modular laboratory automation market report looks at factors such as increasing workload in clinical and diagnostic laboratories, and demand for automation among reference laboratories. However, implementation and integration of automated systems into existing laboratory space, requirement for high capital investments, and risk of prolonged downtime due to automation failure may hamper the growth of the modular laboratory automation industry over the forecast period.
Read the full report: https://www.reportlinker.com/p05834273/?utm_source=PRN
Global Modular Laboratory Automation Market: Overview Rising drug development and research activities The drug R&D sector is witnessing rapid growth with the increase in drug discovery activities and approvals. Drug discovery activities involve safety testing procedures such as validation testing, pharmacogenomic testing, and toxicity testing. This is encouraging drug development researchers to use automation technologies, which are used in safety testing procedures to automate the preanalytical and post-analytical processing. It enhances the process by developing a streamlined workflow and minimizing manual intervention. Thus, the rise in drug development and research activities will lead to the expansion of the global modular laboratory automation market at a CAGR of over 6% during the forecast period. Integration of AI and analytical tools in laboratory workflow Vendors are finding automation and Al as complementing technologies that are together ensuring the optimum utilization of laboratory resources and helping in increasing productivity. The integration of Al and analytical tools has resulted in the introduction of smart modular laboratory automation solutions, which have allowed easy, reliable, and secured networking of automated modules at the field level. Additionally, features such as intelligent control and real-time update about the economic consumption of water and raw materials help provide significant cost benefits to the laboratories deploying such smart systems. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape With the presence of a few major players, the global modular laboratory automation market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading modular laboratory automation manufacturers, that include Agilent Technologies Inc., Becton, Dickinson and Co., Bio-Rad Laboratories Inc., Danaher Corp., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., QIAGEN NV, Shimadzu Corp., Siemens AG, and Thermo Fisher Scientific Inc. Also, the modular laboratory automation market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Read the full report: https://www.reportlinker.com/p05834273/?utm_source=PRN
About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________ Contact Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Read more from the original source:
The global modular laboratory automation market at a CAGR of over 6% during the forecast period - P&T Community
Daniel Streetman,manager of referential content in the Metabolism, Interactions, & Genomics group with Clinical Effectiveness at Wolters Kluwer,discusses the potential for pharmacogenomics to transform prescribed drugs and reduce instances of adverse drug reactions.
Prescribing the correct drug to a patient at the correct dosage is one of the most common daily challenges faced by clinicians, especially when the drug triggers an unexpected side effect.
There are a variety of reasons why drug treatments might not work as anticipated, including the patients genetic profile. This is why more work is now taking place to understand the complex relationship between the genome and drug response, in the fast-growing field of pharmacogenomics.
Pharmacogenomics allows clinicians to use a patients genetic information to guide both drug and dose selection, meaning they become less reliant on a trial-and-error approach to prescribing. During the treatment assessment it quickly becomes possible to identify drugs likely to prove ineffective for a certain patient and whether there are unique dosing or side effect implications. With this added insight, pharmacogenomics could potentially be a game-changer for personalised medicine, having an impact across a wide range of disciplines.
A key challenge in increasing the use of genomics-based information is that many clinicians, operating under extreme pressure, dont understand it or havent had time to process it properly.
This is where clinical decision support tools like Lexicomp a point-of-care drug information resource from Wolters Kluwer has an important role to play in accelerating the use of pharmacogenomics, by making such data easier for clinicians to access.
Lexicomp has built genomics information into drug reference resources, with the aim of highlighting possibly important drug-gene pairings to clinicians in a clear, concise form, with actionable recommendations. The information should be readily available to any professional involved in drug administration, including hospital consultants, first responders, GPs and nurses as well as pharmacists.
Regulators are also encouraging the healthcare sector to embrace genomics. By providing guidance to drug companies on how to introduce biomarker information to their labelling, they have been helping legitimise the role of pharmacogenomics among the wider clinical community.
A major appeal of pharmacogenomics is that it has the potential to impact a wide range of clinical areas. Cardiology, psychology and oncology, for example, are all key areas of investigation. Some researchers also believe that an improved pharmacogenomics infrastructure could be the key to innovation in drug development for Alzheimers Disease, a condition that is projected to have a global cost to society of US$20.8 trillion between 2015-2050.
There is genuine optimism about the potential for pharmacogenomics to move into the mainstream over the next 5-10 years, especially as more patients genetic data becomes available. However, the growth of this new science could also bring challenges. One concern could be over-expectation about the possibilities of pharmacogenomics within the professional community and among patients. In a recent report into the ethics of pharmacogenetics, the Nuffield Council on Bioethics Report touched on the risk of over-promising when it said that genomics might not be about finding the right drug for the right person, but instead suggesting a potential drug preference for genetically defined groups.
Despite some of the concerns, the NHS is well-placed to drive the global pharmacogenomic agenda. The UK is already a pioneer in the field of genetic testing, with a history of sequencing genomes. The cutting-edge work into genomics by the NHS large teaching hospitals and the potential for knowledge and information-sharing between NHS Trusts could deliver these advances at scale and pace for patient benefit.
It will prove far harder for a genomic-based system to develop in countries where the healthcare system is fragmented and siloed and genetic data is less accessible.
The pace of change in genomics will be accelerated further by the new NHS Genomic Medicine Service, which should soon be operational, helping genomic screening and personalised treatments to become the norm. By 2025, it is predicted that half a million whole genomes should be sequenced through different NHS care pathways.
This scale of genomic data will be one of the key drivers to help turn pharmacogenomics from a promising new technology into a mainstream practice, leading to better and safe outcomes for patients.
Dr. Daniel S. Streetman, PharmD, MS, is the manager of referential content in the Metabolism, Interactions, & Genomics group with Clinical Effectiveness at Wolters Kluwer Health. He completed a research fellowship in clinical pharmacology, with an emphasis in pharmacogenomics, at Bassett Healthcare in Cooperstown, NY, and was a clinical faculty member at the University of Michigan for several years prior to joining Wolters Kluwer. Dr. Streetman continues to maintain an academic relationship with several schools, lecturing on pharmacogenomics and other topics.
Read the rest here:
Can connected healthcare lead to better patient outcomes? - EPM Magazine